97963-75-2

Basic information

• Product Name: N-[4-(difluoromethoxy)-2-nitrophenyl]acetamide
• Synonyms: N-[4-(difluoromethoxy)-2-nitrophenyl]acetamide;Pantoprazole Impurity 9
• CAS NO: 97963-75-2
• Molecular Formula: C₉H₈F₂N₂O₄
• Molecular Weight: 246.1676264
• Mol File: 97963-75-2.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 425.3±45.0 °C(Predicted)
• Appearance: /
• Density: 1.451±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 13.01±0.70(Predicted)
• CAS DataBase Reference: N-[4-(difluoromethoxy)-2-nitrophenyl]acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-[4-(difluoromethoxy)-2-nitrophenyl]acetamide(97963-75-2)
• EPA Substance Registry System: N-[4-(difluoromethoxy)-2-nitrophenyl]acetamide(97963-75-2)

Safety Data

• Hazardous Substances Data: 97963-75-2(Hazardous Substances Data)

Usage

Uses

N-(4-Difluoromethoxy-2-nitrophenyl)acetamide is a key reagent used in the preparation of 2-mercapto-5-difluoromethoxy-1H-benzimidazole; an important medicinal intermediate.

Upstream product

• 103-90-2 4-acetaminophenol 
• 22236-11-9 N-[4-(difluoromethoxy)phenyl]-acetamide 

Downstream Products

• 97963-76-3 4-difluoromethoxy-2-nitroaniline 
• 97963-62-7 SKA-47 
• 172282-50-7 4-(difluoromethoxy)benzene-1,2-diamine 

Relevant articles and documents

Diversified synthesis of novel quinoline and dibenzo thiazepine derivatives using known active intermediates

The novel drug development to control resisting infections in conventional drug therapy is a need of today. Few antiulcer relative derivatives developed by approaching convergent synthesis. The derivatives synthesized successfully are dibenzo thiazepine-pyridine (SLN11-SLN15) and benzimidazole-hydroquinoline based derivatives (SLN16-SLN20). It involved the coupling through microwave, sonication and conventional techniques at final step. The efficient technology identified as sonication technique basically time and yield. The reported compounds were structural characterized by elemental analysis and spectral studies such as 1H, 13C NMR and MS.

NICOTINIC ALPHA-7 RECEPTOR LIGANDS AND PREPARATION AND USES THEREOF

The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChR), activation of nAChRs, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds which act as ligands for the α7 nAChR subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

1H-INDAZOLES, BENZOTHIAZOLES, 1,2-BENZOISOXAZOLES, 1,2-BENZOISOTHIAZOLES, AND CHROMONES AND PREPARATION AND USES THEREOF

The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChR), activation of nAChRs, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds (indazoles and benzothiazoles), which act as ligands for the α7 nAChR subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.